The difference of glucostatic parameters according to the remission of diabetes after Roux-en-Y gastric bypass.

Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Diabetes/Metabolism Research and Reviews (Impact Factor: 2.97). 03/2012; 28(5):439-46. DOI: 10.1002/dmrr.2297
Source: PubMed

ABSTRACT Gut hormones play a role in diabetes remission after a Roux-en-Y gastric bypass (RYGB). Our aim was to investigate differences in gut hormone secretion according to diabetes remission after surgery. Second, we aimed to identify differences in insulin secretion and sensitivity according to diabetes remission after RYGB.
Twenty-two severely obese patients with type 2 diabetes underwent RYGB. A meal tolerance test (MTT) was performed 12 months after RYGB. The secretions of active glucagon-like peptide-1 (active GLP-1), glucose-dependent insulinotropic peptide (GIP), peptide YY, C-peptide and insulin during the MTT test were calculated using total area under the curve values (AUC). Remission was defined as glycated haemoglobin (A(1C)) of <6.5% and a fasting glucose concentration of <126 mg/dL for 1 year or more without active pharmacological therapy.
Of the 22 patients, 16 (73%) had diabetes remission (remission group). The secretion CURVES of active GLP-1, GIP and peptide YY were not different between the groups. AUC of insulin and C-peptide were also not different. Homeostasis model assessment estimate of insulin resistance was significantly lower (1.26 ± 1.05 versus 2.37 ± 1.08, p = 0.006), and Matsuda index of insulin sensitivity was significantly higher in the remission group (10.5 ± 6.2 versus 5.8 ± 2.1, p = 0.039). The disposition index (functional reserve of beta cells) was significantly higher in the remission group compared with that in the non-remission group (5.34 ± 2.74 versus 1.83 ± 0.70, p < 0.001).
Remission of diabetes after RYGB is not associated with a difference in gut hormone secretion. Patients remaining diabetic had higher insulin resistance and decreased β cell functional reserve.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Although a few studies have been reported on predictive factors of postoperative diabetes remission, the conclusions remain inconsistent. This meta-analysis aimed to assess the preoperative clinical factors for type 2 diabetes mellitus (T2DM) remission after bariatric surgery.
    Obesity surgery. 08/2014;
  • [Show abstract] [Hide abstract]
    ABSTRACT: Idiopathic intracranial hypertension (IIH) is a disorder of elevated intracranial pressure due to an unknown cause. In most cases, IIH can be managed with medical therapy and weight reduction. Surgical treatment of IIH is reserved for patients who cannot tolerate medical therapy, are nonadherent to medical therapy, develop progressive symptoms despite maximal medical therapy, or present with fulminant visual loss. To date, there has been no randomized controlled trial to evaluate the surgical treatment of IIH, and our current knowledge of the efficacy and complications of these procedures is based on retrospective and observational studies. This review discusses the indications for surgical intervention in IIH and provides an overview of the recently published data on the efficacy and complications of these interventions. A surgical management algorithm is also presented to guide the clinician when evaluating a patient with IIH.
    Current Neurology and Neuroscience Reports 03/2014; 14(3):438. · 3.78 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To evaluate the effect of gastrectomy on diabetes control in patients with type 2 diabetes mellitus and early gastric cancer. Data from 64 patients with early gastric cancer and type 2 diabetes mellitus were prospectively collected. All patients underwent curative gastrectomy (36 subtotal gastrectomy with gastroduodenostomy, 16 subtotal gastrectomy with gastrojejunostomy, 12 total gastrectomy) and their physical and laboratory data were evaluated before and 3, 6 and 12 mo after surgery. Fasting blood glucose (FBS), HbA1c, insulin, C-peptide, and homeostasis model assessment-estimated insulin resistance were significantly improved 3 mo after surgery, regardless of operation type, and the significant improvement in all measured values, except HbA1c, was sustained up to 12 mo postoperatively. Approximately 3.1% of patients stopped diabetes medication and had HbA1c < 6.0% and FBS < 126 mg/dL. 54.7% of patients decreased their medication, and had reduced FBS or HbA1c. In multivariate analysis, good diabetic control was not associated with operation type, but was associated with diabetes duration. Diabetes improved in more than 50% of patients during the first year after gastric cancer surgery. The degree of diabetes control was related to diabetes duration.
    World Journal of Gastroenterology 12/2013; 19(48):9410-7. · 2.55 Impact Factor